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MutantsClassical swine fever virus (CSFV) harbors three envelope glycoproteins (Erns, E1 and E2). Previous studies
have demonstrated that removal of speciﬁc glycosylation sites within these proteins yielded attenuated
and immunogenic CSFV mutants. Here we analyzed the effects of lack of glycosylation of baculovirus-
expressed Erns, E1, and E2 proteins on immunogenicity. Interestingly, Erns, E1, and E2 proteins lacking proper
post-translational modiﬁcations, most noticeable lack of glycosylation, failed to induce a detectable virus
neutralizing antibody (NA) response and protection against CSFV. Similarly, no NA or protection was ob-
served in pigs immunized with E1 glycoprotein. Analysis of Erns and E2 proteins with single site glycosylation
mutations revealed that detectable antibody responses, but not protection against lethal CSFV challenge is af-
fected by removal of speciﬁc glycosylation sites. In addition, it was observed that single administration of pu-
riﬁed Erns glycoprotein induced an effective protection against CSFV infection.rilov), kara.rogers@uconn.edu
ernandez-Sainz),
ca@ars.usda.gov (M.V. Borca),
rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Classical swine fever (CSF) is a highly contagious and often fatal dis-
ease of swine. The etiological agent, classical swine fever virus (CSFV), is
an enveloped virus that is classiﬁed as a Pestivirus within the family Fla-
viviridae (Fauquet et al., 2005). The CSFV genome is a positive sense sin-
gle-stranded RNA that contains a single open reading frame that
encodes an approximately 3900-amino-acid polyprotein. This polypro-
tein is co- and post-translationally processed by host and viral proteases
to yield 11 to 12 ﬁnal cleavage products (NH2–Npro–C–Erns–E1–E2–p7–
NS2–NS3–NS4A–NS4B–NS5A–NS5B–COOH) (Lindenbach et al., 2007).
There are three envelope glycoproteins in the CSFV virion, Erns, E1, and
E2 (Thiel et al., 1991). Erns is loosely associated with mature virions
(Thiel et al., 1991), it possesses ribonuclease activity (Rumenapf et al.,
1993), and is heavily glycosylated with carbohydrate moieties at seven
glycosylation sites contributing to nearly half of the molecular mass of
the protein (Branza-Nichita et al., 2004; Sainz et al., 2008). E1 is asmall 33 kDa protein that forms heterodimers with E2 protein (Weiland
et al., 1990) and contains three glycosylation sites (Fernandez-Sainz
et al., 2009; Thiel et al., 1993). E2 is a major determinant of CSFV viru-
lence (Risatti et al., 2005; Van Gennip et al., 2004) and is involved in
virus attachment and entry into target cells (Hulst and Moormann,
1997). E2 protein contains one putative O-linked glycosylation site and
six N-linked glycosylation sites (Risatti et al., 2007; Thiel et al., 1991;
van Rijn et al., 1994). E2 is the major CSFV immunogen and has been
used to develop subunit vaccines. These vaccines induce protection
against CSFV although the onset of immunity is signiﬁcantly delayed rel-
ative to live attenuated vaccines (Moormann et al., 2000).
The effects of glycan moieties found in these envelope proteins on
induction of host humoral responses and protection against CSFV are
not well understood. For many enveloped viruses (e.g. hepatitis C
virus and human immunodeﬁciency virus) patterns of envelope protein
glycosylation have been shown to inﬂuence the number of available
epitopes and to modulate immune recognition of antigens, affecting
the humoral immune response (Fournillier et al., 2001). In the case of
hepatitis C virus (HCV), carbohydrate moieties on viral envelope pro-
teins modulate neutralizing activity. Using HCV infectious particles, it
was observed that removal of single N-linked glycans at sites N1, N2,
N4, N6 and N11 from E2 protein rendered mutant viruses highly sensi-
tive to neutralization by antibodies from HCV-seropositive patients
(Helle et al., 2010). These data suggest that those glycans reduce the
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protein. Mutation of the fourth glycosylation site in HCV E1, regarded as
a poor immunogenic protein, signiﬁcantly enhanced the anti-E1 hu-
moral response in terms of both seroconversion rates and antibody ti-
ters (Fournillier et al., 2001). In the case of human immunodeﬁciency
virus (HIV) gp120 envelope glycoprotein, proper expression of confor-
mational epitopes is dependent on the integrity and presence of carbo-
hydratemoieties (Haigwood et al., 1992), since fully glycosylated gp120
was found to present neutralizing epitopes more effectively than the
nonglycosylated form of the envelope protein (Haigwood et al., 1992).
Nevertheless, these glycan moieties also have been shown to play a
role in the masking of viral neutralizing epitopes (Back et al., 1993),
leading to the “glycan shield” concept that implicates carbohydrates
in HIV neutralizing antibody resistance (Wei et al., 2003). Similarly, gly-
cosylation of envelope proteins affects immunogenicity of Porcine Re-
productive and Respiratory Syndrome virus (PRRSV). Three putative
N-linked glycosylation sites (N34, N44, and N51) are located on the gly-
coprotein 5 (GP5) ectodomain of PRRSV, where a major neutralization
epitope also exists. Mutations of residue N44 did not result in infectious
progeny, whereas viruses carrying mutations at N34, N51, and N34/51
exhibited enhanced sensitivity to neutralization by wild-type PRRSV-
speciﬁc antibodies. Furthermore, inoculation of pigswith themutant vi-
ruses induced signiﬁcantly higher levels of neutralizing antibodies
against the mutant as well as the wild-type PRRSV, suggesting that
the loss of glycan residues in the ectodomain of GP5 enhances both
the sensitivity of these viruses to in vitro neutralization and the immu-
nogenicity of the nearby neutralization epitope (Ansari et al., 2006).
In previous studies, we have observed that changes in the glycosyl-
ation patterns of CSFV envelope proteins indeed affected virus virulence
and viability (Fernandez-Sainz et al., 2009; Risatti et al., 2007; Sainz et
al., 2008). Those studies showed that substitutions of speciﬁc N residues
to A, in the context of N-glycosylation consensus sequence N-X-S/T
(Kornfeld and Kornfeld, 1985), within CSFV Erns (N269A), E1 (N594A
andN500A/N513A), or E2 (N116L) glycoproteins yielded attenuated vi-
ruses that were also immunogenic, inducing an effective protectionA) Glycosylated forms
B) Non-glycosylated forms
C) Mutant forms
Fig. 1. Schematic representation of classical swine fever virus envelope proteins expressed
encompassing the last 18 amino acids of Core protein (Erns and E1) or the last 16 amino acid
signal peptides (B). Single site glycosylation mutant forms of Erns and E2 proteins were gener
acid residues at indicated glycosylation sites within Erns and E2 proteins (N and O) resulted
sylation) (C). E2 was expressed without the trans-membrane domain. All proteins were exagainst challenge with virulent CSFV as early as day 3 post-inoculation.
Notably, the rest of the single glycosylation site mutant viruses were
virulent in swine, while complete lack of glycosylation of these proteins
in the context of an infectious cDNA clone was deleterious for CSFV
(Fernandez-Sainz et al., 2009; Risatti et al., 2007; Sainz et al., 2008). Al-
though signiﬁcant, these observations limited the study of glycosylation
and its effect on antigenicity and/or immunogenicity of CSFV envelope
proteins. To overcome that limitation,we carried out comparative stud-
ies in swine inoculated with baculovirus-expressed CSFV BICv (strain
Brescia infectious clone virus; Risatti et al., 2005) envelope proteins to
address the role of glycosylation on the induction of humoral immune
response and protection against the virus. Data presented here show
that glycosylated forms of Erns and E2 proteins induced virus neutraliz-
ing antibodies in immunized swine and conferred an effective protec-
tion against CSFV. In contrast, animals immunized with glycosylated
E1 protein did not develop a detectable NA response and succumbed
when exposed to the virulent virus. Interestingly, complete lack of im-
munogenicity was observed when pigs were immunized with nongly-
cosylated forms of the envelope proteins resulting from improper
post-translational modiﬁcations of Erns, E1, and E2 proteins. When
assessing the effect on immunogenicity of individual glycosylation
sites, itwas observed that the removal of single sites fromErns or E2 pro-
teins did not affect their ability to induce a protective immunity against
CSFV, although it had an effect on the induction of the NA response. Re-
sults described here show that glycosylation plays a major role in the
immunogenicity of CSFV envelope proteins, most likely an effect linked
to the correct conformation of Erns, E1, and E2 proteins.
Results
Expression of CSFV envelope proteins
Recombinant baculoviruses harboring CSFV envelope protein genes,
with and without sequences encoding for signal peptides (Fig. 1), were
used to infect Sf9 cells and protein expression was analyzed byin baculovirus. Glycosylated forms of the proteins were expressed with signal peptides
s of E1 protein (E2) (A). Nonglycosylated forms of the proteins were expressed without
ated by site-directed mutagenesis using wild-type genes as targets. Mutations of amino
in N to A substitutions in the consensus N-X-T/S (N-glycosylation) or P to A (O-glyco-
pressed with poly-histidine tags (6× His) for detection and puriﬁcation purposes.
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forms of Erns, E1, and E2 were expressed and recognized by the anti-
His C-terminus antibody. Glycosylated forms of the proteins showed
the expected molecular sizes; Erns 48 kDa, E1 31–32 kDa, and E2
55 kDa (Moser et al., 1996; Ruggli et al., 1995; Rumenapf et al.,
1993). For the glycosylated E1 protein a second band of approximately
26 kDa was also detected (Fig. 2) that may represent different degrees
of glycosylation (Fournillier et al., 2001). The electrophoretic mobility
of Erns, E1, and E2 expressed without signal peptides was found to be
compatible with that of deglycosylated forms of the proteins that
were expressed with signal peptides and previously treated with gly-
cosidase PNGaseF. The molecular weights of nonglycosylated Erns, E1,
and E2 proteins were approximately 25 kDa, 21 kDa, and 41 kDa, re-
spectively, and corresponded to their predicted mass calculated from
the amino acid composition, indicating the absence of proper glycosyl-
ation (Fig. 2) (Ruggli et al., 1995).
Recombinant baculoviruses harboring Erns and E2 mutated genes
encoding for single N to A substitutions at N-glycosylation sites (N-X-
T/S) and at the predicted O-glycosylation site in E2 protein were used
to infect Sf9 cells. The differences in electrophoretic mobility observed
among expressed Erns, and E2 mutated proteins (Supplementary
Fig. S1) corresponded to the differences observed in lysates from SK6
cells infected with glycosylation mutant viruses (Risatti et al., 2007;
Sainz et al., 2008).
Immunogenicity of CSFV envelope proteins
To investigate the effect of modiﬁed forms of envelope proteins on
the immunogenicity and protective efﬁcacy against CSFV, pigs were in-
oculated with puriﬁed glycosylated or nonglycosylated forms of the
CSFV envelope proteins. Animals were boosted at days 28, 42, and 56
after the ﬁrst inoculation, and challenged IN one week after the last in-
oculation with a virus (BICv) derived from an infectious clone of the
highly virulent isolate Brescia (Risatti et al., 2005). Pigs vaccinated
with glycosylated Erns and E2 were protected and survived challenge
without showing clinical signs of the disease (Table 2). Only a mild
and transient increase in body temperature was observed in two out
of four animals inoculated with glycosylated E2 protein. Conversely,
animals inoculated with nonglycosylated forms of Erns and E2
proteins succumbed to the challenge, and showed signs of the disease in-
distinguishable from those observed in control animals. These data
indicate that lacking proper post-translationalmodiﬁcations,most notice-
able lack of glycosylation, signiﬁcantly affects immunogenicity of Erns
and E2 proteins. Along with those observations, viremia in challenged
animals immunized with nonglycosylated forms of Erns and E2 wasN G PkDa N G P N G P
Erns E1 E2
60
50
40
30
20
Fig. 2. Western blot analysis of baculovirus-expressed nonglycosylated (N), glycosy-
lated (G), or glycosylated PNGase F-treated lysate (P) forms of CSFV BICv (Risatti et
al., 2005) envelope proteins Erns, E1, and E2. Lysates from Sf9 cells inoculated with re-
combinant baculoviruses were separated under denaturing conditions in 10% Bis–Tris
gels followed by detection with anti-his C-term antibody (Invitrogen).indistinguishable from viremia observed in control pigs (Figs. 3A and B).
All these animals succumbed to infection no later than 14 dpc. Immuniza-
tionwith Erns or E2 glycoproteins elicited a response that resulted in virus
titers in blood approximately 100-fold lower relative to control pigs
(Figs. 3A and B). Clearance of challenging virus was observed by 21 dpc
in the Erns glycoprotein group and by 14 to 21 dpc in the E2 glycoprotein
group. Overall, data suggest that correct topology and structure of Erns and
E2 glycoproteins is necessary for eliciting an effective immune response
against CSFV.
Pigs immunized with glycosylated or nonglycosylated form E1
protein were not protected against BICv (Table 2), developing CSF
signs characterized by anorexia, depression, and an onset of fever
by 3–4 dpc, ultimately succumbing to the infection within 8 to 14
dpc. E1 protein administered as puriﬁed protein does not induce pro-
tection against CSFV.
Antibody response in immunized pigs
The ability of glycosylated and nonglycosylated forms of Erns and
E2 proteins to induce antibodies in swine was tested by ELISA and
seroneutralization following immunization.
Using ELISA, only animals immunized with glycosylated forms of
Erns and E2 proteins showed an antibody response (Fig. 4A). Similarly,
neutralizing antibodies titers (NA) measured against BICv showed
that immunization with nonglycosylated forms of Erns or E2 did not
elicit detectable NAs (Fig. 4B), correlating with the lack of immunoge-
nicity induced in swine by these forms of the proteins. ELISA and NA
data suggest that lack of proper conformation of Erns and E2 glycopro-
teins considerably affects the exposure of critical epitopes.
NAs were induced by immunization with glycosylated forms of
the proteins (Fig. 4B), correlating with the observed induction of pro-
tection against BICv. The NA response induced by glycosylated E2 oc-
curred earlier than the response in pigs immunized with glycosylated
Erns. NA titers of 1:500 or higher were detected in serum samples
from all animals at day 7 after the second dose of glycosylated E2
(Fig. 4B). A sustained antibody response was observed in this group
of pigs until challenge, when NA titers in all the animals were
detected above 1:2000. NA titers in pigs immunized with glycosy-
lated Erns were detected in one animal (#79=1:128) at day 7 after
receiving a second dose of the protein, whereas a uniform response
was observed in all pigs only by 14 days post-third immunization
(Fig. 4B). Notably, NA titers in this group of animals were 1:64 by
the time of challenge, and in spite of rather reduced Erns antigenicity
compared with that of E2, the induced antibody response precluded
the appearance of CSF signs in these animals.
Immunogenicity of Erns glycoprotein
The ﬁnding that puriﬁed glycosylated Erns elicited low levels of NA
titers but induced protection against challenge with BICv after four
immunizations prompted analysis of whether or not this protein
was still immunogenic after a fewer number of inoculations. Three
different groups of pigs were intramuscularly immunized with one,
two or three doses of Erns glycoprotein at 14 day intervals (Fig. 5)
and challenged at 21 days after the last inoculation. Interestingly, pro-
tection against challenge was achieved even when pigs received only
one dose of Erns (Table 3). Neither Erns antibodies nor virus neutraliz-
ing antibodies against CSFV were detected in sera collected from
these animals (Fig. 5C), although these pigs seroconverted by day 7
after challenge (data not shown). Animals that received 2 or 3 doses
of Erns presented low NA titers at challenge (Figs. 5A and B) and
were clearly seropositive by ELISA. These data suggest either a low
sensitivity of the antibody detection test used to quantify NAs, or ad-
ditional yet unidentiﬁed immune mechanisms (i.e. non-neutralizing
antibodies), are contributing to protection against CSFV induced by
glycosylated Erns.
Table 1
Sequences of the oligonucleotide primers used for synthesis of glycosylated and nonglycosylated forms of Erns, E1, and E2 proteins.
Primer name Sequencea
Erns nonglycosylated forward 5′ CACCATGGAAAATATAACTCAA 3′
Erns glycosylated forward 5′ CACCATGGCCCTATTGGCATGGGCAGTGATAGCAATTATGTTATACCAACCTGTTGCAGCCGAAAATATAACTCAA 3′
Erns reverse 5′ TTAGTGATGGTGATGGTGATGGGCATAGGCACCAAA 3′
E1 nonglycosylated forward 5′ CACCATGCTATCACCTTATTGT 3′
E1 glycosylated forward 5′ CACCATGGCCCTATTGGCATGGGCAGTGATAGCAATTATGTTATACCAACCTGTTGCAGCCCTATCACCTTATTGT 3′
E1 reverse 5′ TTAGTGATGGTGATGGTGATGGCCTTGTGCCCCAGT 3′
E2 nonglycosylated forward 5′ CACCATGCGGCTAGCCTGCAAG 3′
E2 glycosylated forward 5′ CACCATGGTCGTGCAAGGTGTGATATGGCTGTTACTGGTAACTGGGGCACAAGGC
CGGCTAGCCTGCAAG 3′
E2 reverse 5′ TTAGTGATGGTGATGGTGATGTTCTGCGAAGTAATC 3′
a Signal peptides shown in italics; his-tag sequences shown underlined.
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mutated Erns and E2 glycoproteins
Since modiﬁed Erns and E2 lacking proper glycosylation abrogated
the antibody and the protective response in inoculated pigs, we
assessed if any of the individual glycosylation sites present in these
proteins were critical in the induction of the antibody response. Ani-
mals were immunized with single site glycosylation mutated Erns
protein or E2 protein (Supplementary Fig. S1) and challenged with
BICv as described above. Sera obtained from these animals were test-
ed for the presence of antibodies.
No detectable NAs were present in sera from pigs that received
mutated forms of Erns protein. However, sera from all these animals
tested positive by ELISA 7 days after receiving a second dose of the
proteins (data not shown).
NAswere detected in sera from pigs immunizedwith single site gly-
cosylation mutated forms of E2 protein by 7 days after the second inoc-
ulation (Fig. 6). Sera from pigs immunized with O1, N1, N2, N3, and N4
exhibited signiﬁcantly lower NA titers compared to sera from animals
immunized with E2 protein (Fig. 6), whereas mutations at N5 and N6
did not affect E2 immunogenicity (Fig. 6). Overall, most of the E2 single
glycosylation mutations diminished the antigenicity of E2 protein.
Protection elicited by single glycosylation site mutated Erns
and E2 glycoproteins
The contribution of single glycosylation sites in Erns andE2 proteins in
conferring protection against CSFV was assessed by challenging immu-
nized pigs (see above)with virulent BICv.While non-immunized control
pigs succumbed to the lethal infection, all animals immunized with mu-
tated forms of either glycoprotein survived the challenge and were pro-
tected against clinical disease after four inoculations, with the exception
of pigs immunized with Erns N3, Erns N7, and E2 N2 proteins; these ani-
mals exhibited elevated body temperatures for more than 6 days
(Table 4), a temporary loss of appetite and mild depression. Viremia
was detected in all groups of immunized animals and for the same ap-
proximate length of time. Virus titers in animals immunized withTable 2
Swine survival and fever response following vaccination of swine with glycosylated and no
Protein No. of
survivors/
total no.
Mean time to
death (no. of days±SDa)
Fever
No. of da
Erns nonglycosylated 0/6 13 (1.0) 3.5 (0.5
Erns glycosylated 6/6 –b 2.67 (1.5
E1 nonglycosylated 0/2 13.5 (0.5) 4 (0.0
E1 glycosylated 0/2 14.5 (5.5) 3.5 (0.5
E2 nonglycosylated 0/6 13.5 (0.5) 2.5 (1.5
E2 glycosylated 6/6 – 7c (1.0
a SD: standard deviation.
b “–” negative.
c Only 2 animals out of total of 6 inoculated animals.mutated forms of Erns or E2 tended to be higher than virus titers detected
with native forms of the proteins. Nonetheless, in all cases, virus titers
were signiﬁcantly lower in animals immunized with different forms of
Erns or E2 than in mock-vaccinated animals (Figs. 7A and B).Recombinant E2 single glycosylation mutant viruses have differential
sensitivity to NAs raised against glycosylated E2 protein
The ﬁnding that immunizationwithmutated forms of Erns and E2 eli-
cited differential NA responses against BICv (Fig. 6) prompted the oppo-
site analysis, where the neutralizing activity of sera raised against
glycosylated E2 was determined against recombinant E2 glycosylation
mutant viruses (Risatti et al., 2007). E2N1v, a mutant virus harboring a
N116A substitution in E2, was signiﬁcantly more resistant to neutraliza-
tion by sera raised against glycosylated E2 than BICv (NAb titers of 220
vs. 603 respectively, pb0.05, t-test). Meanwhile E2N4v, a mutant virus
harboring a N229A substitution in E2, was signiﬁcantly more sensitive
to neutralization by sera raised against glycosylated E2 than BICv (NAb
titers of 1494 vs. 603 respectively, pb0.05, t-test). The reactivity to neu-
tralization of the rest of the mutant viruses was similar to BICv (data not
shown). The data suggest that mutations at these glycosylation sites
may lead to conformational changes in E2 protein that either shield or
expose important neutralizing epitopes.Discussion
Glycosylation of viral envelope proteins inﬂuences the immuno-
genicity and the sensitivity of the virus to neutralizing antibodies.
By maintaining the appropriate conformation of proteins, oligosac-
charides may hinder proteolytic degradation and with that affect T-
cell recognition (Li et al., 2008; Sodora et al., 1991). Removal of gly-
cans from viral envelope proteins has been shown to enhance (Doe
et al., 1994; Reitter et al., 1998; Wei et al., 2003), interfere with
(Sjolander et al., 1996), or have no effect on their immunogenicity
(Bolmstedt et al., 1996). In this study we characterized the role of
glycosylation of the three CSFV envelope proteins, analyzed its abilitynglycosylated Erns, E1, and E2 proteins.
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Fig. 3. Means and standard deviations of virus titers in blood from pigs immunized with nonglycosylated (n=4) and glycosylated (n=4) forms of Erns (A); and nonglycosylated
(n=4) and glycosylated (n=4) forms E2 (B) proteins and challenged with BICv. dpc: days post-challenge. Values expressed as log10 TCID50/ml. Sensitivity of the assay ≥1.80
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induce protection in swine against challenge with highly virulent CSFV.
Four conclusions can be drawn from this study: (i) only glycosylated
Erns and E2 proteins were able to induce a NA response and protection
against CSFV in swine; (ii) E1 glycoprotein was not immunogenic nor
protective against CSFV even in its native form and after four immuniza-
tions; (iii) puriﬁed Erns glycoprotein was immunogenic, inducing an ef-
fective protection against CSF in swine even after one immunization;
and (iv) the immunogenicity of Erns and E2 glycoproteins is greatly af-
fected by speciﬁc glycosylation sites.
(i) Sera from swine inoculated with nonglycosylated forms of the
Erns and E2 envelope proteins failed to neutralize CSFV infection
of SK6 cells. A similar effect has been previously observed forHIV (Benjouad et al., 1992), where no neutralizing activity was
observed in sera from rabbits immunized with deglycosylated
forms ofmajor envelope protein gp160. However, in those studies
the sera from these rabbits recognized gp160 by RIA; sera from
swine immunized with non-glycosylated forms of Erns or E2 did
not react with the proteins in competitive ELISA tests. The per-
centages of inhibition in sera from pigs after four immunizations
with nonglycosylated forms of Erns or E2 were similar to those
of pre-immune sera. It is likely that modiﬁcations induced in
these envelope proteins lacking proper post-translational modiﬁ-
cations, noticed by complete lack of glycosylation, results in con-
formational changes that affect exposure of important epitopes
that mediate the NA response against CSFV and induce protection
against the virus. Here, we found that only glycosylated Erns and
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establishing a strong protective response against CSFV.
(ii) The baculovirus-expressed E1 glycoprotein did not induce a de-
tectable NA response in sera from immunized pigs even after
administration four times as an oil-in-water emulsion. Under
these conditions, E1 did not elicit a protective response since
challenged animals succumbed to infection with virulent CSFV.
The poor immunogenicity of E1 protein was also observed in an-
imals vaccinated with recombinant competent vaccinia virus
that succumbed to CSFV infection when challenged intranasally
5 weeks post-vaccination (Konig et al., 1995). As observed here,
those animals did not show detectable antibodies against the
protein before challenge, although high antibody titers against
the vector were detected. This suggests that E1 protein may
not play a signiﬁcant role in immunity against CSFV.(iii) Puriﬁed Erns protein induced an effective protective response
against CSFV. The immunogenicity of Erns was observed ﬁrst in
pigs vaccinated with a replication competent recombinant vac-
cinia virus that resisted CSFV infection when challenged
5 weeks post-vaccination (Konig et al., 1995). In those animals
there were no detectable NA a week before challenge and sera
contained only non-neutralizing antibodies detectable by
ELISA. Different from the experiments performed here, antigens
expressed by recombinant vaccinia viruses are delivered into
eukaryotic cells and usually elicit high levels of cytotoxic T lym-
phocytes (CTL) (Moss, 1991, 1992), leading to effective antiviral
activity (Byrne and Oldstone, 1984). However, no CTL epitopes
have been reported for Erns protein. We also observed that pro-
tected pigs, challenged 21 days after a single vaccination with
the Erns protein, did not have detectable NAs or ELISA-detectable
Table 3
Swine survival and fever response in pigs immunized with different doses of glycosy-
lated Erns proteins and challenged with BICv.
No. of doses
(×)
No. of
survivors/
total no.
Mean
time
to
death
(no. of
Fever
No. of days to
onset (±SD)
Duration (no.
of days±SD)
Max temp,
°C (±SD)
141B.K. Gavrilov et al. / Virology 420 (2011) 135–145antibodies at the time of exposure to CSFV. Rather, antibodies
against Erns were detected by 7 days post-challenge at much
higher titers than in mock immunized animals, indicating a
boosting effect by the virus infection, whereas NAs were
detected later, by 10 days post-challenge. This rapid onset of hu-
moral immunity observed after exposure to CSFV may have
played a role in virus clearance and disease progression. The ap-A
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2/2 –b 3.0 (0.00) 1.0 (0.00) 40.8 (0.77)
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2/2 – – – 39.7 (0.00)
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a SD: standard deviation.
b “–” negative.
Fig. 5. Antibody response in pigs immunized with different number of doses of glyco-
sylated Erns protein before challenge with BICv. Pigs (n=2) were inoculated intramus-
cularly three times at days 0, 14, and 28 and challenged 7 days after last vaccination
(A), twice (n=2) on days 0 and 14 and challenged 21 days after last vaccination (B)
or once (n=2) and challenged 21 days after last vaccination (C). Not shown are ani-
mals (n=2) immunized with 3 doses of Erns challenged at 21 days after last vaccina-
tion. Serum samples were collected weekly after the ﬁrst immunization and antibody
titers were detected by ELISA and measured by seroneutralization. NA titers are
expressed as log 2 of the reciprocal of the highest serum dilution neutralizing approx-
imately 100 TCID50 of BICv and antibodies detected by ELISA are expressed as percent-
age of inhibition (see Materials and methods). dpv: days post-vaccination.parent lack of NA titers in protected animals may be the result of
the presence of undetectable but still efﬁcacious levels of NAs.
Alternatively, protection may be mediated by still undeﬁned im-
mune mechanisms. Nevertheless, these mechanisms are likely
to be antibody-mediated (i.e.: antibody-mediated cytotoxicity
or antibody-complement-mediated cytotoxicity) since the in-
duction of T-cell mediated mechanisms in animals immunized
with puriﬁed protein preparations it is less plausible.
(iv) Individual glycosylation sites in Erns and E2 proteins have an ef-
fect on the induction of humoral responses after immunization.
Glycan moieties may limit the antigenicity of viral envelope pro-
teins and restrict the binding of some antibodies to key epitopes.
Contrary to what has been observed for other viruses, removal of
individual glycosylation sites from Erns and E2 proteins did not
result in enhancement of the antibody response in vaccinated
pigs. Rather, vaccination with ﬁve of the E2 mutated proteins
resulted in lower NA titers (O1, N1, N2, N3, and N4) relative to
fully glycosylated protein, suggesting that NA induction depends
on the presence of these glycosylation sites. Data from cross-
neutralization studies between E2 sera and recombinant glyco-
sylation mutant viruses E2N1v and E2N4v indicate that N1 and
N4 sites in the E2 protein affect antigenicity of the protein, an ef-
fect compatible with structural changes that affect proper expo-
sure of neutralizing epitopes. Interestingly, N1 and N2 sites are
located towards the N-terminus of E2 between two proposed
structural units of the proteins, conformed by domains D and A
(van Rijn et al., 1994). Both structural units contain neutralizing
epitopes. N3 and N4 sites reside in an area of E2 still structurally
undeﬁned. Eventually, alteration of glycosylation patterns in E2
might affect exposure of currently unidentiﬁed epitopes. None-
theless all mutated proteins were able to induce a protective im-
munity after four immunizations. Further mapping of these
glycosylation sites will be required to determine what combina-,
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Fig. 6. Development of NAs in pigs immunized with E2 single site glycosylation mutants. Pigs (n=2 per group) were inoculated intramuscularly with each mutant forms of E2 at
days 0, 28, 42, and 56 and challenged 1 week after last immunization. Shown are NA titers from a week previous to seroconversion. NA titers are expressed as log 2 of the reciprocal
of the highest serum dilution neutralizing approximately 100 TCID50 of BICv (see Materials and methods). Error bars correspond to standard deviations.
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as observed here with nonglycosylated forms of the protein. Sim-
ilarly, vaccination with Erns mutated proteins did not result in en-
hancement of the antibody response. Removal of individual sites
greatly affected the production of NAs, since immunization with
glycosylation mutated proteins did not induce detectable NAs,
while fully glycosylated Erns induced a NA response detectable
by 14 days post-third immunization. In both cases animals were
protected against lethal CSFV challenge. Clearly, immunogenicity
of Erns is dependent on glycosylation.Table 4
Swine survival and fever response in pigs immunized with Erns and E2 single site gly-
cosylation mutant forms of the proteins and challenged with BICv.
Protein No. of
survivors/
total no.
Time of
death
(dpc)
(±SDa)
Time of the
onset of fever
(dpc) (±SD)
Duration of
fever (days)
(±SD)
Maximal
temperature
(°C) (±SD)
Erns 1/1b – 7 (0.00) 1(0.00) 40.1 (0.00)
Erns N1 2/2 – 3 (4.24) 0.5 (0.70) 40 (0.21)
Erns N2 2/2 – 3.5 (4.94) 2 (2.82) 40 (0.28)
Erns N3 2/2 – 3 (2.82) 6.5 (3.58) 41 (1.13)
Erns N4 2/2 – 2.5 (3.53) 1 (1.41) 40 (0.42)
Erns N5 2/2 – 2 (2.82) 3.5 (4.94) 40.4 (0.35)
Erns N6 2/2 – 4.5 (0.70) 3.5 (3.53) 40.3 (0.14)
Erns N7 1/1b – 4 (0.00) 6 (0.00) 41.6 (0.00)
E2 2/2 – 4 (4.24) 3 (2.82) 40.2 (0.21)
E2O1 2/2 – – – 39.8 (0.00)
E2N1 2/2 – 2.5 (3.53) 3.5 (4.94) 40.6 (0.91)
E2N2 2/2 – 3.5 (2.12) 8.5 (0.70) 40.8 (0.07)
E2N3 2/2 – 3.5 (4.94) 0.5 (0.70) 40.3 (0.63)
E2N4 2/2 – 6.5 (9.19) 1.5 (2.12) 40 (0.42)
E2N5 2/2 – 7 (9.89) 1.5 (2.12) 40.1 (0.35)
E2N6 1/1b – – – 39.6 (0.14)
Control 0/2 11.5 (4.94) 3 (0.00) 9 (4.24) 42 (0.00)
“–” negative.
a One of the two animals in each of these groups died at early stages of the
immunization period by unrelated causes.
b Standard deviation.In summary, the results presented here indicate that neutralizing
epitopes in Erns and E2 proteins are dependent on the presence of glyco-
sylation; most probably, as E2 data suggests, critical glycosylation sites
are located within certain domains of this protein (i.e. D/A domains).
We show that preventing proper post-translational modiﬁcation in
Erns and E2 that mainly results in lack of glycosylation lead to the syn-
thesis of non-immunogenic proteins that failed to induce protection
against CSFV, while removal of single glycosylation sites did not signiﬁ-
cantly affect the overall immunogenicity of these proteins. We observed
that only puriﬁed Erns and E2 glycoproteins mediate immunity against
CSFV, since glycosylated and nonglycosylated forms of E1 protein failed
to induce a detectable antibody response and failed to induce protection
in vaccinated pigs. A highly signiﬁcant observation was that a single
dose of puriﬁed Erns induces protection against CSFV although the
exact mechanism(s) mediating that protection remains uncertain.
It is possible that observations presented here will be useful for
designing subunit vaccines against CSFV.
Materials and methods
Cells and viruses
Propagation of recombinant baculoviruses and expression of the
envelope proteins were performed in the Spodoptera frugiperda de-
rived Sf9 cell line. Sf9 cells were maintained in adherent cultures in
Grace's insect cell culture medium (TNM-FH) supplemented with
10% fetal bovine serum and gentamicin (Lonza, Walkersville, MD).
Swine kidney cells (SK6) (Terpstra et al., 1990), free of BVDV,
were used to propagate CSFV BICv (Risatti et al., 2005) and glycosyl-
ation mutant viruses (Fernandez-Sainz et al., 2009; Risatti et al.,
2007; Sainz et al., 2008). SK6 cells were cultured in Dulbecco's mini-
mal essential medium (Invitrogen, Carlsbad, CA) with 10% fetal bo-
vine serum (Lonza).
For titration of CSFV from clinical samples, SK6 cells in 96-well
plates (Corning, Lowell, MA) were infected and incubated at 37 °C
and 5% CO2 for 4 days. Viral infectivity was detected using an immu-
noperoxidase assay with the CSFV monoclonal antibody (mAb)
WH303 (Edwards et al., 1991) and the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA). Titers were calculated according to
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Fig. 7. Average of virus titers in blood from pigs, two pigs per group, immunized with Erns single site glycosylation mutants (A), or E2 single site glycosylation mutants (B) after
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tissue culture infective dose (TCID50)/ml. As performed, test sensitiv-
ity was ≥ log10 1.8 TCID50/ml.
Generation of recombinant baculoviruses
Polymerase chain reaction (PCR) was utilized to synthesize CSFV
BICv Erns, E1, and E2 genes using speciﬁc sets of primers (Table 1). Re-
verse primers included sequences encoding for six histidine residues
(6×-HIS) to allow protein detection and puriﬁcation by immobilized-
metal afﬁnity chromatography. Sets of forward primers with or with-
out sequences encoding for putative CSFV signal peptides (Moser
et al., 1996; Ruggli et al., 1995; Rumenapf et al., 1993; van Rijn et al.,
1996) were used to synthesize glycosylated and nonglycosylatedforms of the three envelope protein genes. The E2 gene was synthe-
sized without its transmembrane region (Hulst et al., 1993) to facilitate
its subsequent expression and puriﬁcation. The resulting PCR frag-
ments were eluted from a 1% agarose gel using the QIAEX II Gel Extrac-
tion Kit (Qiagen, Valencia, CA), and cloned directionally into pENTR/D-
TOPO entry vector (Invitrogen). To conﬁrm that inserted genes were in
frame, entry clones were veriﬁed by automatic sequencing.
Single site glycosylationmutated Erns and E2 genes were obtained by
site-directedmutagenesis (QuikChangeMulti Site-DirectedMutagenesis
Kit, Agilent Technologies, Santa Clara, CA) using speciﬁc primers (Risatti
et al., 2007; Sainz et al., 2008) (Table 1). pENTR/D-TOPO vectors harbor-
ing Erns or E2 genes were used as template in those reactions.
Recombinant baculoviruses were produced using the BaculoDirect C-
Term expression system (Invitrogen) according to the manufacturer's
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proteins were constructed by an attL-attR recombination reaction be-
tween entry clones and BaculoDirect Linear DNA containing the Herpes
Simplex Virus thymidine kinase gene located between recombination
sites for negative selection with ganciclovir. Sf9 cells were transfected
using Cellfectin (Invitrogen) and subsequently propagated as recom-
mended in the protocol provided by the manufacturer. Cells were
grown until signs of infection were observed (6–8 days after transfec-
tion). The resulting stock (P1) was harvested and ampliﬁed once by
infecting conﬂuent Sf9 cells to obtain a high-titer viral stock (P2).
Detection and puriﬁcation of recombinant proteins
Sf9 cells (about 1.5×106/ml) were infected at MOI=5 or 10 with
recombinant baculoviruses and cells and culture media were har-
vested after incubation at 27 °C for 5 to 7 days. Cultures were centri-
fuged at 2000×g for 5 min at 4 °C and the cell pellet was washed
twice with phosphate-buffered saline (PBS) followed by resuspension
in RIPA buffer (Sigma Aldrich, St. Louis, MO). After incubation for
10 min on ice, preparations were clariﬁed by centrifugation at
16,100×g for 10 min. Expression of the recombinant envelope pro-
teins was veriﬁed by Western blot analysis. Brieﬂy, protein lysates
were separated under reducing conditions on a 10% NuPage Novex
Bis–Tris gel (Invitrogen) by a discontinuous SDS-PAGE system and
transferred to polyvinylidene ﬂuoride (PVDF) membrane (Invitro-
gen). Membranes were blocked, and then incubated overnight with
anti-his C-term antibody (Invitrogen) at a dilution of 1:5000. Mem-
branes were washed and incubated with goat anti-mouse IgG anti-
body conjugated with alkaline phosphatase (WesternBreeze
Chemiluminescent Detection Kit, Invitrogen). Envelope proteins
were detected using CDP-star chemiluminescent substrate provided
with the kit and by exposing to X-ray ﬁlms (Kodak X-OMAT LS ﬁlm,
Kodak, Rochester, NY).
For puriﬁcation, protein lysates were applied to HisPur Cobalt
Resin Columns (Thermo Fisher Scientiﬁc, Rockford, IL) and puriﬁed
following the manufacturer's instructions. The collected fractions
were analyzed byWestern blotting as described above and Coomassie
blue staining (Simply Blue SafeStain, Invitrogen).
As control for deglycosylation of envelope proteins, glycosylated
envelope proteins were treated with peptide N-Glycosidase F (PNGase
F, New England Biolabs, Ipswich, MA) following the manufacturer's di-
rections. Brieﬂy, infected cell extracts were denatured at 100 °C for
10 min in glycoprotein denaturing buffer (New England BioLabs). The
reaction mixture was placed on ice for 5 min, and then digested with
PNGase F for 1 h at 37 °C in the presence of 1% NP-40.
Protein concentration was determined by the BCA Protein Assay
(Thermo Fisher Scientiﬁc) against bovine serum albumin standard,
by measuring OD at 595 nm in a NanoDrop (NanoDrop Technologies,
Wilmington, DE).
Animal experiments
Eighteen to twenty kiliograms, 2 to 3 months old, commercial breed
pigs were used in all these experiments. In all cases, pigs were inoculat-
ed with puriﬁed envelope proteins mixed with Sigma Adjuvant System
(Sigma-Aldrich, St. Louis, MO) to obtain an oil-in-water emulsion
according to instructions given by the manufacturer. One milliliter of
each inoculum containing ~50 μg of puriﬁed protein was injected via
intramuscular route into the neck of animals. Mock-vaccinated animals
received adjuvant alone. After immunization pigs were challenged in-
tranasally (IN) with 105 TCID50 of highly virulent BICv.
For initial screening, pigs (n=14) were allocated randomly into 6
groups (n=2). A mock-vaccinated control group (n=2) was also in-
cluded. Pigs were inoculated with nonglycosylated or glycosylated
forms of Erns, E1, or E2 proteins and boosted with the same dose 28,
42, and 56 days later. Blood samples were collected from each animalweekly starting from the day of ﬁrst inoculation. Pigs were challenged
1 week after the last inoculation. After challenge, pigs were observed
daily for 28 days for manifestation of CSF clinical signs (anorexia, de-
pression, purple skin discoloration, staggering gait, diarrhea, and
cough). Body temperatures were recorded daily throughout the
experiment.
For conﬁrmatory purposes, pigs (n=18) were randomly allocated
into one of four vaccination groups (n=4) or a mock-vaccination
control group (n=2). Pigs were inoculated with nonglycosylated or
glycosylated forms of Erns or E2 proteins (vaccinated groups) or
non-vaccinated (control group). Protein concentrations, route of in-
oculation, adjuvant formulations, vaccination schedule, and challenge
were performed as described above. Blood, serum, nasal swabs, and
tonsil scrapings were collected from each pig at 0, 3, 7, 10, 14, 21,
and 28 days post-challenge (dpc).
The protective efﬁcacy of glycosylated Erns protein was further
assessed in swine. Pigs (n=10) were allocated into 4 vaccine groups
(n=2) and 1 non-vaccinated control group (n=2). Pigs were inocu-
lated as described above. Two vaccine groups received 3 doses of gly-
cosylated Erns at 2-week intervals (days 0, 14, and 28) and were
challenged at 7 and 21 days post-third inoculation, respectively. A
third vaccine group received 2 doses of glycosylated Erns at 2-week
interval (days 0 and 14) and was challenged at 21 days post-second
inoculation. The fourth vaccine group received 1 dose of glycosylated
Erns (day 0) and was challenged at 21 days post-inoculation. Serum
samples were obtained weekly after vaccination.
To assess the immunogenicity of single site glycosylation Erns and
E2 mutated proteins, pigs (n=34) were randomly allocated into six-
teen vaccinated groups (n=2), and a mock-vaccinated control group
(n=2). Seven vaccinated groups received single site glycosylation
mutated Erns proteins (N1, N2, N3, N4, N5, N6, and N7) (Figs. 1 and
Supplementary Fig. S1A). Seven vaccinated groups received single
site glycosylation mutated E2 proteins (O1, N1, N2, N3, N4, N5, and
N6) (Figs. 1 and Supplementary Fig. S1B). Two vaccinated groups re-
ceived glycosylated Erns and E2 proteins, respectively. The control
group was mock vaccinated. Animals were inoculated with these pro-
teins at days 0, 28, 42, and 56 and then challenged 1 week after the
last vaccination.
Antibody detection
Serum samples were analyzed for the presence of CSFV Erns specif-
ic antibodies using commercial ELISA kits: IDEXX CHEKIT CSF MARK-
ER ELISA Test Kit (Idexx Laboratories, Westbrook, ME) for detection of
antibodies against Erns and detection of anti-E2 antibodies was per-
formed with IDEXX CSF SERO Antibody ELISA Test Kit (Idexx Labora-
tories). ELISA test kits were used according to the protocols provided
by the manufacturer.
Seroneutralization and cross-neutralization assays were per-
formed with heat-inactivated serum samples (56 °C for 30 min).
Two-fold serial dilutions of serum were prepared in Dulbecco's mod-
iﬁed Eagle's medium (DMEM) supplemented with 10% FBS andmixed
with equal volumes of BICv or glycosylation mutant viruses (Risatti
et al., 2007; Sainz et al., 2008) containing 102 TCID50. Serum-virus
mixtures were incubated for 1 h at 37 °C and then transferred to 96-
well ﬂat-bottom tissue culture plates (Corning) followed by addition
of SK6 cells (1×104 per well). Plates were incubated at 37 °C and 5%
CO2 for 4 days. Supernatant was then removed from each well and
the cells were ﬁxed with methanol–acetone (50% vol./vol.) solution
and air-dried. Plates were stained by immunoperoxidase assay using
the Vecstatin ABC Kit, Vector Laboratories, Burlingame, CA following
manufacturer's instructions. Neutralizing antibody titers were
expressed as the reciprocal of the highest two-fold serum dilution
neutralizing BICv (Reed and Muench, 1938).
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.virol.2011.08.025.
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